Background: Management of metastatic castration refractory prostate cancer (CRPC) is
rapidly evolving. Rationalisation of treatment requires identification of those patients more …

Methods We identified 197 chemotherapy-naive patients who received abiraterone at six BC
Cancer Agency centres and who had complete information on all six RFs. Study endpoints …

Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall
survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) post …

Aim: To evaluate abiraterone in patients with metastatic castration-resistant prostate cancer
(mCRPC). Methods: This is a multicenter retrospective analysis, involving 44 consecutive …

Methods: Consecutive patients with mCRPC who received abiraterone post-docetaxel were
identified using centralized pharmacy records. These patients came from 5 Canadian tertiary …

Purpose The aim of this study was to evaluate the efficacy of abiraterone in patients with
castration‐resistant metastatic prostate cancer. Materials and methods We retrospectively …

Coadministration of docetaxel and abiraterone acetate plus prednisone (AA+ P) may benefit
patients with metastatic castration-resistant prostate cancer (mCRPC) because of …

Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is
approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC) …

Background To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone
compared with prednisone alone in Asian patients with chemotherapy-naive metastatic …

We aimed to identify clinical predictors of long-term response to abiraterone (defined as> 12
months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate …